Join to View Full Profile
675 N Saint Clair StGalter 20150Chicago, IL 60611
Phone+1 312-695-8146
Fax+1 312-695-3185
Dr. Meeks is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
McGaw Medical Center of Northwestern UniversityResidency, Urology, 2007 - 2011- McGaw Medical Center of Northwestern UniversityResidency, Surgery, 2005 - 2007
- Northwestern University The Feinberg School of MedicineClass of 2005
Certifications & Licensure
IL State Medical License 2008 - 2026
NY State Medical License 2011 - 2026
American Board of Urology Urology
Publications & Presentations
PubMed
- 1 citationsUrine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.Marie-Pier St-Laurent, Parminder Singh, David J McConkey, M Scott Lucia, Vadim S Koshkin
European Urology. 2025-11-01 - Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse Molecular and Microenvironment Ecosystems.Khyati Meghani, Yanni Yu, Noah Frydenlund, Erik Z Li, Bonnie Choy
European Urology. 2025-10-06 - 1 citationsLow-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.Lexiaochuan Wen, Hiroko Miyagi, Philippe E Spiess, Alice Yu, Cathy L Mendelsohn
Nature Reviews. Urology. 2025-09-10
Journal Articles
- T1 Bladder Cancer: Current Considerations for Diagnosis and ManagementJoshua J Meeks, Brian Jordan, Nature
- Development of a Translational Medicine Protocol for an NCTN Genitourinary Clinical Trial: Critical Steps, Common Pitfalls and a Basic Guide to Translational Clinical ...Joshua Meeks, MD, Urologic Oncology
Authored Content
- Frequency of Testing for Prostate Cancer Using Prostate-Specific Antigen Among Older Men in a Large Health SystemNovember 2018
- Discrepancies in Staging, Treatment, and Delays to Treatment May Explain Disparities in Bladder Cancer Outcomes: An Update from the National Cancer Data Base (2004–2013)January 2018
Press Mentions
Bladder Cancer Treatment Landscape Is Advancing, at LastAugust 12th, 2025- ASCO 2025: Trials-in-Progress – Intravesical Sacituzumab Tirumotecan in Participants with Intermediate-Risk Non–Muscle-Invasive Bladder Cancer: The Phase 1/2 TroFuse-027 StudyJune 3rd, 2025
- Combination Treatment Extends Survival in Advanced Bladder CancerSeptember 17th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
